Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …

Acquired haemophilia A (AHA) is a rare bleeding disorder caused by inhibitory
autoantibodies against coagulation factor VIII (FVIII). AHA is a disease that most commonly …

Background Acquired haemophilia A (AHA) is a rare bleeding disorder due to
autoantibodies to coagulation factor VIII that may be secondary to autoimmune diseases …

Obstetric and gynecological hemorrhage remains a frequent and severe complication that
affects women at childbearing age and at the period of their full physical and professional …

Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …

Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a
sudden and unexpected bleeding episode in a patient with no personal or family history of …

Background In 2016, a new recombinant B-domain deleted porcine FVIII (rpFVIII) was
licensed in Italy for the treatment of acquired haemophilia A (AHA), but only a few cases of …

Background: Acquired hemophilia A (AHA) is a rare bleeding disease due to autoantibodies
directed against clotting factor VIII (FVIII). Treatment of AHA consists of inhibitor eradication …

Krwotoki położnicze i ginekologiczne są nadal częstym i ciężkim powikłaniem występującym
u kobiet w wieku rozrodczym oraz okresie pełnej aktywności fizycznej i zawodowej. Problem …